Annexin Pharmaceuticals (Q4 review): Phase II study away, with positive initial results - Redeye

Redeye comments on Annexin’s Q4 report and recent events and see good initial progress in the phase II study. We adjust our financial assumptions and FX a bit, resulting in a slightly revised valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/1147539/annexin-pharmaceuticals-q4-review-phase-ii-study-away-with-positive-initial-results?utm_source=finwire&utm_medium=RSS